Opportunity Information: Apply for RFA DK 15 028
The National Institutes of Health (NIH) funding opportunity titled "Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (DP3)" (Funding Opportunity Number RFA DK 15 028; CFDA 93.847) supports clinical studies that evaluate how current and emerging diabetes technologies perform specifically in older adults living with type 1 diabetes. The central idea is that tools such as advanced blood glucose monitoring systems and insulin delivery approaches may offer meaningful benefits, but the real-world balance of risks and advantages could look different in older patients than it does in younger populations that are often the focus of technology trials. NIH is therefore encouraging research that directly tests these technologies in older adults, with an emphasis on measurable health outcomes, glucose management, and day-to-day quality of life.
A key motivation for the program is that older adults with type 1 diabetes can be more vulnerable to serious hypoglycemia and may also face cognitive impairment, functional limitations, or multiple co-existing medical conditions. These factors can influence whether a technology is safe, usable, and beneficial. For example, a device that improves time-in-range in a younger adult might create new challenges for an older person who has visual impairment, reduced manual dexterity, difficulty interpreting alarms, or limited caregiver support. Likewise, co-morbidities and polypharmacy can change hypoglycemia risk or complicate self-management routines. The FOA is aimed at generating evidence that accounts for these age-related and clinical complexities rather than assuming that outcomes will generalize across age groups.
The clinical studies encouraged under this announcement are intended to determine whether technologies for glucose monitoring and insulin administration lead to improvements in outcomes that matter to older adults, including better glucose control and fewer adverse events, while also addressing patient-centered outcomes such as independence, treatment burden, confidence in self-management, and overall quality of life. Although the announcement description is broad, it clearly frames the research around practical, health-impacting questions: how well these technologies work in older people with T1D, what risks they introduce or reduce (especially around hypoglycemia), and how they affect everyday living in a population that may have distinct needs and constraints.
This is a discretionary grant opportunity within the NIH mission areas related to health and nutrition. A wide range of organizations are eligible to apply. Eligible applicants include various levels of government (state, county, city/township, and special district governments), public and state-controlled institutions of higher education, private institutions of higher education, independent school districts, and public or Indian housing authorities. The eligibility list also includes federally recognized Native American tribal governments and other Native American tribal organizations, nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories), for-profit organizations other than small businesses, and small businesses. In addition, the announcement explicitly highlights eligibility for a number of institution types and organizations that are often emphasized in federal research programs, including Alaska Native and Native Hawaiian Serving Institutions, Asian American and Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations). This breadth signals an intent to encourage diverse research settings and populations, including studies that may be embedded in community, tribal, or regionally focused healthcare environments.
Administrative details in the source indicate the FOA was created on September 24, 2015, with an original closing date of March 3, 2016. The funding instrument type is a grant, and it is categorized under discretionary funding. The provided source excerpt does not specify an award ceiling or the expected number of awards, suggesting those details either were not included in the excerpted fields or may have been defined elsewhere in the full announcement.
Overall, this opportunity is focused on producing clinically meaningful, age-relevant evidence about diabetes technology use in older adults with type 1 diabetes, with explicit attention to safety concerns like hypoglycemia and real-life challenges such as cognitive impairment and multiple co-morbidities. The intended end result is clearer guidance on which monitoring and insulin-delivery technologies improve health outcomes and quality of life for older patients, and under what conditions they are most effective and safest.Apply for RFA DK 15 028
- The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (DP3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2015-09-24.
- Applicants must submit their applications by 2016-03-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this NIH funding opportunity?
The funding opportunity is titled "Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (DP3)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA DK 15 028.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.847.
What type of funding instrument is used for this opportunity?
The funding instrument type is a grant.
Is this a discretionary or mandatory funding opportunity?
This is a discretionary grant opportunity.
What kinds of studies does this FOA support?
This FOA supports clinical studies that evaluate how current and emerging diabetes technologies perform specifically in older adults living with type 1 diabetes.
What is the main purpose of the research encouraged by this program?
The program is intended to generate evidence on how glucose monitoring and insulin administration technologies affect health outcomes and quality of life in older adults with type 1 diabetes, recognizing that risks and benefits may differ from those seen in younger populations.
What types of diabetes technologies are the focus of the FOA?
The FOA focuses on technologies for glucose monitoring and insulin delivery, including advanced blood glucose monitoring systems and insulin delivery approaches.
Why does NIH emphasize studying these technologies in older adults rather than relying on evidence from younger populations?
The FOA highlights that older adults with type 1 diabetes may have different vulnerabilities and real-world constraints (for example, higher hypoglycemia risk, cognitive impairment, functional limitations, and multiple co-existing medical conditions). These factors can affect safety, usability, and overall benefit in ways that may not be captured in studies centered on younger people.
What health risks in older adults with type 1 diabetes are specifically mentioned as a motivation for this research?
The FOA specifically notes vulnerability to serious hypoglycemia, and also points to cognitive impairment, functional limitations, and multiple co-existing medical conditions as factors that may influence technology performance and safety.
What usability or day-to-day challenges for older adults are mentioned in the description?
The description mentions that issues such as visual impairment, reduced manual dexterity, difficulty interpreting alarms, and limited caregiver support can create challenges for older adults using diabetes technologies.
How do co-morbidities and polypharmacy relate to the goals of this FOA?
The FOA notes that co-morbidities and polypharmacy can change hypoglycemia risk and complicate self-management routines, which is part of why technologies must be evaluated in older adults under real-world, age-related complexities.
What outcomes are these clinical studies expected to measure?
The FOA emphasizes measurable health outcomes, glucose management, and adverse events (especially hypoglycemia), along with patient-centered outcomes that matter to older adults.
What patient-centered outcomes are specifically highlighted?
The FOA highlights outcomes such as independence, treatment burden, confidence in self-management, and overall quality of life.
Does the FOA focus only on glucose control metrics?
No. While glucose control and safety outcomes are central, the FOA also emphasizes day-to-day quality of life and other patient-centered outcomes relevant to older adults.
What is the overarching question this FOA is trying to answer?
The FOA is centered on practical, health-impacting questions: how well glucose monitoring and insulin-delivery technologies work in older adults with type 1 diabetes, what risks they introduce or reduce (particularly around hypoglycemia), and how they affect everyday living for a population with distinct needs and constraints.
When was this FOA created?
The administrative details provided state that the FOA was created on September 24, 2015.
What was the original closing date listed for this opportunity?
The original closing date listed is March 3, 2016.
Who is eligible to apply?
A wide range of organizations are eligible, including various levels of government, public and private institutions of higher education, independent school districts, public or Indian housing authorities, federally recognized tribal governments and other tribal organizations, nonprofits (with or without 501(c)(3) status, as specified), for-profit organizations other than small businesses, and small businesses.
Are state, county, city, township, or special district governments eligible applicants?
Yes. The eligibility list includes state governments, county governments, city or township governments, and special district governments.
Are colleges and universities eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are independent school districts eligible?
Yes. Independent school districts are included in the eligibility list.
Are public or Indian housing authorities eligible to apply?
Yes. Public and Indian housing authorities are included as eligible applicants.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized Native American tribal governments and other Native American tribal organizations are eligible.
Are nonprofits eligible, and does 501(c)(3) status matter?
Yes. Nonprofits with or without 501(c)(3) status are listed as eligible, with the caveat in the provided description that these nonprofit categories are eligible as long as they are not institutions of higher education in those categories.
Are for-profit organizations eligible?
Yes. The eligibility list includes for-profit organizations other than small businesses, and it also separately lists small businesses as eligible.
Are small businesses eligible to apply?
Yes. Small businesses are included in the eligibility list.
Does the FOA highlight participation from specific institution types such as HBCUs or Hispanic-serving institutions?
Yes. The announcement explicitly highlights eligibility for institution types and organizations often emphasized in federal research programs, including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and other serving institution categories.
Are faith-based or community-based organizations eligible?
Yes. The announcement explicitly includes faith-based or community-based organizations in the highlighted eligibility list.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly included in the highlighted eligibility list.
Are non-U.S. entities (foreign organizations) eligible to apply?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).
Does the provided information list an award ceiling or the expected number of awards?
No. The provided source excerpt does not specify an award ceiling or the expected number of awards, indicating those details were not included in the excerpted fields or may exist elsewhere in the full announcement.
What is the expected impact of research funded under this opportunity?
The stated intent is to produce clinically meaningful, age-relevant evidence about diabetes technology use in older adults with type 1 diabetes, with attention to safety (especially hypoglycemia) and real-life challenges, ultimately supporting clearer guidance on which technologies improve health outcomes and quality of life and under what conditions they are most effective and safest.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: PPHF 2016: Epidemiology and Laboratory Capacity Program for Infectious Diseases – Building and Strengthening Epidemiology, Laboratory and Health Information Systems Capacity in State and Local Health Departments – Financed in part by 2016 Prev
Previous opportunity: Bipartisan Infrastructure Law (BIL) - Clean Fuels & Products Shot: Supporting Carbon Utilization Products via Electrochemical Conversion and Refinery and Petrochemical Facilities Retrofitting
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 15 028
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 15 028) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Using Biosamples and Subjects from Type 1 Diabetes Clinical Studies Complications (DP3) Apply for RFA DK 15 019 Funding Number: RFA DK 15 019 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) Apply for RFA DK 25 024 Funding Number: RFA DK 25 024 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers (U24 Clinical Trial Not Allowed) Apply for RFA DK 25 015 Funding Number: RFA DK 25 015 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Polycystic Kidney Disease Core Centers (U54 Clinical Trial Not Allowed) Apply for RFA DK 25 016 Funding Number: RFA DK 25 016 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional) Apply for RFA DK 25 018 Funding Number: RFA DK 25 018 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $800,000 |
| Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional) Apply for RFA DK 25 017 Funding Number: RFA DK 25 017 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $350,000 |
| Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed) Apply for PAR 24 258 Funding Number: PAR 24 258 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed) Apply for RFA DK 26 002 Funding Number: RFA DK 26 002 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not Allowed) Apply for RFA DK 25 021 Funding Number: RFA DK 25 021 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed) Apply for RFA DK 25 022 Funding Number: RFA DK 25 022 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $400,000 |
| Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed) Apply for PAS 25 205 Funding Number: PAS 25 205 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional) Apply for RFA DK 26 001 Funding Number: RFA DK 26 001 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) Apply for PAR 25 277 Funding Number: PAR 25 277 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA DK 25 023 Funding Number: RFA DK 25 023 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) Apply for RFA DK 26 006 Funding Number: RFA DK 26 006 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required) Apply for PA 25 147 Funding Number: PA 25 147 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 25 089 Funding Number: PAR 25 089 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional) Apply for PAS 25 073 Funding Number: PAS 25 073 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional) Apply for PAR 25 097 Funding Number: PAR 25 097 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $125,000 |
| Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed) Apply for PAR 25 068 Funding Number: PAR 25 068 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 15 028", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.